Ameriprise
BIOA

Ameriprise’s BioAge Labs BIOA Stock Holding History

Ameriprise’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Sell
59,133
-23,830
-29% -$459K ﹤0.01% 3285
2025
Q4 		$1.1M Buy
82,963
+52,500
+172% +$465K ﹤0.01% 3284
2025
Q3 		$179K Sell
30,463
-13,571
-31% -$63.5K ﹤0.01% 3918
2025
Q2 		$182K Buy
+44,034
New +$177K ﹤0.01% 3826

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise's BIOA Position: Q1 2026 in Review

Ameriprise reduced its BioAge Labs (BIOA) stake by 29% in Q1 2026, selling an estimated $459K and leaving 59,133 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3285.

Ameriprise first reported a position in BIOA in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.1M in Q4 2025. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • Ameriprise held 59,133 shares of BioAge Labs worth $1.03M as of Q1 2026.
  • Ameriprise sold 23,830 BioAge Labs shares in Q1 2026, an estimated $459K.
  • BioAge Labs made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3285 holding.
  • Ameriprise first reported a position in BioAge Labs in Q2 2025 and has held it in 4 quarters since.
  • Ameriprise's BioAge Labs position peaked at $1.1M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.